- Home
- SYBT vs BEAM Comparison
SYBT vs BEAM Comparison
Compare SYBT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- BEAM
- Stock Information
- Founded
- SYBT 1904
- BEAM 2017
- Country
- SYBT United States
- BEAM United States
- Employees
- SYBT N/A
- BEAM N/A
- Industry
- SYBT Major Banks
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYBT Finance
- BEAM Health Care
- Exchange
- SYBT Nasdaq
- BEAM Nasdaq
- Market Cap
- SYBT 2.2B
- BEAM 1.9B
- IPO Year
- SYBT N/A
- BEAM 2020
- Fundamental
- Price
- SYBT $73.25
- BEAM $24.05
- Analyst Decision
- SYBT Hold
- BEAM Buy
- Analyst Count
- SYBT 4
- BEAM 11
- Target Price
- SYBT $65.25
- BEAM $45.90
- AVG Volume (30 Days)
- SYBT 201.0K
- BEAM 1.3M
- Earning Date
- SYBT 10-23-2024
- BEAM 11-05-2024
- Dividend Yield
- SYBT 1.69%
- BEAM N/A
- EPS Growth
- SYBT N/A
- BEAM N/A
- EPS
- SYBT 3.63
- BEAM N/A
- Revenue
- SYBT $331,807,000.00
- BEAM $349,643,000.00
- Revenue This Year
- SYBT N/A
- BEAM N/A
- Revenue Next Year
- SYBT $7.24
- BEAM $6.04
- P/E Ratio
- SYBT $20.18
- BEAM N/A
- Revenue Growth
- SYBT 1.02
- BEAM 328.73
- 52 Week Low
- SYBT $42.35
- BEAM $20.84
- 52 Week High
- SYBT $77.82
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- SYBT 61.71
- BEAM 46.67
- Support Level
- SYBT $71.87
- BEAM $21.46
- Resistance Level
- SYBT $77.82
- BEAM $32.29
- Average True Range (ATR)
- SYBT 2.33
- BEAM 2.04
- MACD
- SYBT 0.47
- BEAM 0.19
- Stochastic Oscillator
- SYBT 68.48
- BEAM 23.92
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates a majority of its revenue from the Commercial Banking segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.